RBC Capital Maintains Outperform on NewAmsterdam Pharma, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev maintains an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and raises the price target from $25 to $31.
February 29, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on NewAmsterdam Pharma and increased the price target from $25 to $31.
The increase in price target by a reputable analyst like Leonid Timashev signals a strong confidence in NewAmsterdam Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100